At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Etokimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy
In Brief
A Phase 2 clinical trial evaluating Etokimab and Placebo for Peanut Allergy. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine etokimab safety, tolerability and activity in adult participants with peanut allergy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Allergy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartJan 2017
Primary CompletionMar 2018
TodayJul 2026
First PostedSep 30, 2016
Enrollment StartJan 26, 2017
Primary CompletionMar 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.8 years ago
Interventions
Etokimabdrug
Humanized monoclonal antibody, administered by intravenous infusion
Placebodrug
Administered by intravenous infusion